Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lilach Vaks"'
Autor:
Ido Rippin, Katherina Bonder, Shirley Joseph, Ammar Sarsor, Lilach Vaks, Hagit Eldar-Finkelman
Publikováno v:
Neurobiology of Disease, Vol 154, Iss , Pp 105336- (2021)
In Huntington's disease (HD), the mutant huntingtin (mHtt) accumulates as toxic aggregates in the striatum tissue, with deleterious effects on motor-coordination and cognitive functions. Reducing the levels of mHtt is therefore a promising therapeuti
Externí odkaz:
https://doaj.org/article/046c34e9ec654364a9ccf8bd0fb54142
Autor:
Lilach Vaks, Dana Litvak-Greenfeld, Stav Dror, LeeRon Shefet-Carasso, Galia Matatov, Limor Nahary, Shiran Shapira, Rahely Hakim, Iris Alroy, Itai Benhar
Publikováno v:
Antibodies, Vol 7, Iss 3, p 27 (2018)
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising t
Externí odkaz:
https://doaj.org/article/b8e5a2a749c5447c9e18022c94bf9c22
Autor:
Shirley Ben Joseph, Lilach Vaks, Amar Sarsor, Ido Rippin, Katherina Bonder, Hagit Eldar-Finkelman
Publikováno v:
Neurobiology of Disease, Vol 154, Iss, Pp 105336-(2021)
In Huntington's disease (HD), the mutant huntingtin (mHtt) accumulates as toxic aggregates in the striatum tissue, with deleterious effects on motor-coordination and cognitive functions. Reducing the levels of mHtt is therefore a promising therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82430bd6e6a6fc9dbff5516f0ea00373
https://pubmed.ncbi.nlm.nih.gov/33753290
https://pubmed.ncbi.nlm.nih.gov/33753290
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1904
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not possible with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2bef99f972b77b65b6c9a9158cb9fb7f
https://pubmed.ncbi.nlm.nih.gov/30539485
https://pubmed.ncbi.nlm.nih.gov/30539485
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1904
Monoclonal antibodies (mAbs) are currently the fastest growing class of therapeutic proteins. Parallel to full-length IgG format the development of recombinant technologies provided the production of smaller recombinant antibody variants. The single-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::401ef5f192c5cff05dbc40124dd5dea5
https://pubmed.ncbi.nlm.nih.gov/30539486
https://pubmed.ncbi.nlm.nih.gov/30539486
Publikováno v:
Methods in Molecular Biology ISBN: 9781493989577
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not possible with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c29ec16368e1740597e53fcf0396c02
https://doi.org/10.1007/978-1-4939-8958-4_22
https://doi.org/10.1007/978-1-4939-8958-4_22
Publikováno v:
Methods in Molecular Biology ISBN: 9781493989577
Monoclonal antibodies (mAbs) are currently the fastest growing class of therapeutic proteins. Parallel to full-length IgG format the development of recombinant technologies provided the production of smaller recombinant antibody variants. The single-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adab4b2e4887a712dd49da3da2d21c0e
https://doi.org/10.1007/978-1-4939-8958-4_23
https://doi.org/10.1007/978-1-4939-8958-4_23
Autor:
Stav Dror, Shiran Shapira, LeeRon Shefet-Carasso, Lilach Vaks, Limor Nahary, Itai Benhar, Rahely Hakim, Galia Matatov, Dana Litvak-Greenfeld, Iris Alroy
Publikováno v:
Antibodies
Volume 7
Issue 3
Antibodies, Vol 7, Iss 3, p 27 (2018)
Volume 7
Issue 3
Antibodies, Vol 7, Iss 3, p 27 (2018)
Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not achievable with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52f74b09343c1bfdf6d5d59fe6376ffe
Autor:
Batya Plotkin, Lilach Vaks, Limor Avrahami, Avital Licht-Murava, Miriam Eisenstein, Hagit Eldar-Finkelman, Rom Paz
Publikováno v:
Science Signaling. 9
Development of protein kinase inhibitors is a focus of many drug discovery programs. A major problem, however, is the limited specificity of the commonly used adenosine triphosphate-competitive inhibitors and the weak inhibition of the more selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15328b6eb2c971bf37fc059f6c253973
https://doi.org/10.1126/scisignal.aah7102
https://doi.org/10.1126/scisignal.aah7102
Autor:
Lilach, Vaks, Itai, Benhar
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1060
Monoclonal antibodies (mAbs) are currently the fastest growing class of therapeutic proteins. Parallel to full-length IgG format the development of recombinant technologies provided the production of smaller recombinant antibody variants. The single-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e71f2eac1e47004bc5be48ac3707a094
https://pubmed.ncbi.nlm.nih.gov/24037842
https://pubmed.ncbi.nlm.nih.gov/24037842